About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:3850443
Allelic
Composition
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (232 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• following adenoviral cre treatment, median survival time is 135 days

neoplasm
• following adenoviral cre treatment, 86% of mice develop thoracic tumors (including malignant mesotheliomas, 45 of 55; rhabdomyosarcomas, 2 of 55; and schwannomas, 1 of 55)
• following adenoviral cre treatment, mice develop either non-aggressive epitheloid or mixed tumors with confined invasion of the visceral pleural or (sarcomatoid) tumors with strong invasion of visceral and parietal pleura
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus
• following adenoviral cre treatment, 11% of mice develop aspecific tumors not induced by adeno-cre treatment
• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles
• a few following adenoviral cre treatment
• in 7% of mice following adenoviral cre treatment
• following adenoviral cre treatment, 7% mice develop monocytic myeloid leukemias
• following adenoviral cre treatment, latency to developing malignant mesotheliomas is lower than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles

liver/biliary system
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

muscle
• in 7% of mice following adenoviral cre treatment

endocrine/exocrine glands
• a few following adenoviral cre treatment

growth/size/body
• following adenoviral cre treatment, 4% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

reproductive system
• in 7% of mice following adenoviral cre treatment

nervous system

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
malignant mesothelioma DOID:1790 OMIM:156240
J:132943


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory